Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

128

...

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L03AX03	BCG-MEDAC	G	BCG seed RIVM derived from seed 1173-P2 - 2x10? to 3x10? viable units		Injectable powder for suspension+diluent	L.L
L03AX13	GLITAXON	G	Glatiramer acetate - 20mg/ml	20mg/ml	Injectable solution	10,146,988 L.L
L03AX16	MOZOBIL	B	Plerixafor - 20mg/ml	20mg/ml	Injectable solution	413,801,327 L.L
L03AX16	PLERIXAFOR ARROW	G	Plerixafor - 20mg/ml	20mg/ml	Injectable solution	289,660,995 L.L
L03AX16	REVIXIL 20	G	Plerixafor - 20mg/ml	20mg/ml	Injectable solution	248,280,900 L.L
L04AA04	THYMOGLOBULINE 5mg/ml	BioTech	Rabbit anti-human thymocyte immunoglobulin - 25mg/5ml	25mg/5ml	Injectable powder for solution	21,928,046 L.L
L04AA06	IMUNOCELL	G	Mycophenolate mofetil - 500mg	500mg	Tablet, film coated	L.L
L04AA06	MYFORTIC	B	Mycophenolic acid (sodium) - 360mg	360mg	Tablet, gastroresistant	20,324,991 L.L
L04AA06	CELLCEPT	B	Mycophenolate mofetil - 250mg	250mg	Capsule	6,083,575 L.L
L04AA06	CELLCEPT	B	Mycophenolate mofetil - 500mg	500mg	Tablet	6,083,575 L.L
L04AA06	IMUNOCELL	G	Mycophenolate mofetil - 500mg	500mg	Tablet, film coated	3,791,428 L.L
L04AA06	MMF	G	Mycophenolate mofetil - 500mg	500mg	Tablet, coated	4,087,969 L.L
L04AA06	MYORA	G	Mycophenolate mofetil - 500mg	500mg	Tablet, film coated	3,643,157 L.L
L04AA06	MYFORTIC	B	Mycophenolic acid (sodium) - 360mg	360mg	Tablet, gastroresistant	L.L
L04AA10	RAPAMUNE	B	Sirolimus - 1mg	1mg	Tablet	12,907,489 L.L
L04AA10	SIROMUNE	G	Sirolimus - 1mg	1mg	Tablet, film coated	18,729,193 L.L
L04AA10	RAPAMUNE	B	Sirolimus - 1mg	1mg	Tablet	L.L
L04AA13	ARAVA	B	Leflunomide - 10mg	10mg	Tablet, film coated	2,230,779 L.L
L04AA13	AROTAN	G	Leflunomide - 10mg	10mg	Tablet, film coated	1,527,949 L.L
L04AA13	ARAVA	B	Leflunomide - 20mg	20mg	Tablet, film coated	3,346,168 L.L
L04AA13	AROTAN	G	Leflunomide - 20mg	20mg	Tablet, film coated	2,014,420 L.L
L04AA18	CERTICAN	B	Everolimus - 0.5mg	0.5mg	Tablet	26,832,962 L.L
L04AA18	CERTICAN	B	Everolimus - 0.75mg	0.75mg	Tablet	26,832,962 L.L
L04AA18	CERTICAN	B	Everolimus - 0.5mg	0.5mg	Tablet	L.L
L04AA18	CERTICAN	B	Everolimus - 0.75mg	0.75mg	Tablet	L.L
L04AA23	TYSABRI	BioTech	Natalizumab - 300mg/15ml	300mg/15ml	Injectable concentrated solution	L.L
L04AA23	TYSABRI	BioTech	Natalizumab - 300mg/15ml	300mg/15ml	Injectable concentrated solution	126,830,594 L.L
L04AA27	GILENYA	B	Fingolimod - 0.5mg	0.5mg	Capsule	166,452,693 L.L
L04AA27	FINGOLIMOD ZENTIVA	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule, hard	32,406,715 L.L
L04AA27	LYXIA	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule, hard	32,406,715 L.L

...

128

...